News

Pharmaceuticals

Next Phase of Pharma Growth: Generics

Michael McTague | Equities.com |

Here Come the Generics!

Investors have been rattled by many pieces of bad news for months but the massive pharmaceutical industry brings some relief. For 2022, Pfizer (PFE) is looking at an additional $20 billion in revenue over last year, actually a repeat of its 2021 versus 2020 performance. Their assets are way up and feature $31 billion in cash. Johnson and Johnson (JNJ), which is looking at more than $95 billion in revenue this year, has about the same...


Big Pharma and The Need for Speed

Michael McTague | Equities.com |

In the pharmaceutical world, fast delivery offers a critical advantage. The market knows that obesity, diabetes, cardiovascular disease, dementia and cancer pose great dangers for the aging populations of many countries. My last column looked at pharmaceutical breakthroughs and their massive benefits. Once a breakthrough is achieved, and after the euphoria of the scientific achievement ebbs, production, shipping and distribution take center stage. 

For...


AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement

Equities Staff | Equities.com |

The companies are facing over 3,500 opioid-related lawsuits.


WHO Endorses Pfizer's Oral COVID-19 Treatment Paxlovid for High-Risk Patients

Equities Staff | Equities.com |

Paxlovid may be the most potent COVID-19 therapy currently available.


Eton Pharmaceuticals — Small Cap Orphan Drug + Royalty Hybrid With Multiple FDA Arrows

Edward Kim | Equities.com |

Eton now has six FDA-approved commercial products in launch phase with four additional submissions that have been made to the FDA.


Global Pharmaceutical Companies Pledge Support for Ukraine's Healthcare System

Equities Staff | Equities.com |

The latest attack ordered by Putin has only exacerbated the humanitarian crisis in Ukraine.


Moderna Cuts COVID-19 Vaccine Sales Forecast; Shares Plunge 16%

Reuters | Equities.com |

Moderna Inc (MRNA) on Thursday slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, as it struggles to fill vials and distribute them around the world, sending its shares down nearly 15% before the opening bell.

Moderna executives said production challenges now lie with bottling up doses, also known as fill and finish, and ramping up infrastructure to deliver them internationally, rather than production of raw material.


Pfizer Shares Set Intraday Record, Pacing COVID-19 Vaccine Makers

Reuters | Equities.com |

Shares of Pfizer Inc hit a record high on Tuesday for the first time in more than 20 years as shares of COVID-19 vaccine makers have surged amid rising coronavirus cases in the United States.

Pfizer shares were last up 4.9% at $48.25, climbing as high as $48.57 during the session. The stock's previous intraday high was $47.44, reached on April 12, 1999.


Johnson & Johnson Beats Q2 Estimates, Raises Full-Year Guidance

Reuters | Equities.com |

Johnson & Johnson on Wednesday forecast $2.5 billion in 2021 sales for its COVID-19 shot and set a lower production target for the vaccine as lengthy manufacturing problems took a toll.

The company now expects to produce 500 million to 600 million doses of its one-shot vaccine this year, Chief Financial Officer Joseph Wolk told CNBC on Wednesday, down from its original goal to produce a billion shots this year.


Philip Morris To Acquire UK Pharma Vectura for $1.4 Billion, Topping Carlyle's Bid

Reuters | Equities.com |

Marlboro cigarettes maker Philip Morris International agreed on Friday to buy British drugmaker Vectura for 1.05 billions pounds ($1.44 billion) to bolster its portfolio of products that are free from tobacco or nicotine.

The deal, which topped a proposal by investment firm Carlyle Group, means shareholders in the drugmaker that makes 13 inhaled medicines will get 150 pence per share in cash, 11% higher than its Thursday closing price.


Sponsored Financial Content

Market Movers